From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.
telisotuzumab vedotin 
GtoPdb Ligand ID: 13908
|
Synonyms: ABBV-399 | ABBV399 | ABT-700-vcMMAE | Emrelis® | Teliso-V | telisotuzumab vedotin-tllv
telisotuzumab vedotin is an approved drug
Compound class:
Antibody
Comment: Telisotuzumab vedotin (ABBV-399; ABT-700) is an antibody-drug conjugate (ADC). It is a conjugate of the anti-hepatocyte growth factor receptor (HGFR; c-Met) antibody ABT-700 and the cytotoxic microtubule inhibitor MMAE (or vedotin) [4]. It was designed for anti-tumour activity in malignancies with MET amplification and/or c-Met overexpression, and that express constitutive c-Met signalling or ligand-dependent activation of c-Met.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Bioactivity Comments |
| Binds to human and monkey c-Met but not to mouse c-Met [4]. |
| Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License